| http://www.w3.org/ns/prov#value | - Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with Triumeq is recommended in patients with underlying hepatic disease such as hepatitis B or C. Hepatic decompensation, some fatal, has occurred in HIV-1/Hepatitis C Virus (HCV) coinfected patients receiving combination antiretroviral therapy and interferon alfa with or without ribavirin.
|
